Moreover, a recent study in which patients with urothelial cancer were treated with the anti-PD-L1 agent, atezolizumab, showed that PD-L1 expression on tumor immune infiltrate was associated with improved clinical responses [6]. The gene discussed is CD274; the disease is neoplasm.